PFM Health Sciences, LP 13D and 13G filings for Adaptimmune Therapeutics plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:06 pm Sale |
2022-12-31 | 13G | Adaptimmune Therapeutics plc ADAP |
PFM Health Sciences, LP | 29,061,060 3.000% |
-25,597,620 (-46.83%) |
Filing |
| 2022-05-09 4:51 pm Purchase |
2022-04-28 | 13G | Adaptimmune Therapeutics plc ADAP |
PFM Health Sciences, LP | 54,658,680 5.800% |
54,658,680 (New Position) |
Filing |